CA2020199C

CA2020199C - Utilisation de sucres sulfates

Utilisation de sucres sulfates Download PDF

Info

Publication number: CA2020199C
Authority: CA; Canada
Prior art keywords: disaccharide; mono; sulphated; skin; saccharide
Prior art date: 1990-06-29
Legal status : Expired - Fee Related

Application number

CA 2020199

Other languages

English (en)

Other versions

CA2020199A1 (fr

Inventor

Daniel Bar-Shalom

Niels Bukh

Current Assignee

Buhk Meditec AS

Original Assignee

Buhk Meditec AS

Priority date

1990-06-29

Filing date

1990-06-29

Publication date

2002-08-20

1990-06-29 Application filed by Buhk Meditec AS filed Critical Buhk Meditec AS

1990-06-29 Priority to CA 2020199 priority Critical patent/CA2020199C/fr

1991-12-30 Publication of CA2020199A1 publication Critical patent/CA2020199A1/fr

2002-08-20 Application granted granted Critical

2002-08-20 Publication of CA2020199C publication Critical patent/CA2020199C/fr

2010-06-29 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

150000008163 sugars Chemical class 0.000 title description 2
235000000346 sugar Nutrition 0.000 title 1
238000011282 treatment Methods 0.000 claims abstract description 74
238000002360 preparation method Methods 0.000 claims abstract description 51
150000002016 disaccharides Chemical class 0.000 claims abstract description 37
150000002772 monosaccharides Chemical class 0.000 claims abstract description 36
230000000699 topical effect Effects 0.000 claims abstract description 31
239000002674 ointment Substances 0.000 claims abstract description 30
230000004054 inflammatory process Effects 0.000 claims abstract description 27
206010061218 Inflammation Diseases 0.000 claims abstract description 25
210000001519 tissue Anatomy 0.000 claims abstract description 25
150000003839 salts Chemical class 0.000 claims abstract description 23
239000003814 drug Substances 0.000 claims abstract description 22
239000000843 powder Substances 0.000 claims abstract description 22
241001465754 Metazoa Species 0.000 claims abstract description 21
208000015181 infectious disease Diseases 0.000 claims abstract description 21
239000000725 suspension Substances 0.000 claims abstract description 21
210000002808 connective tissue Anatomy 0.000 claims abstract description 18
238000011321 prophylaxis Methods 0.000 claims abstract description 16
239000000243 solution Substances 0.000 claims abstract description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
239000000499 gel Substances 0.000 claims abstract description 14
230000003211 malignant effect Effects 0.000 claims abstract description 13
239000006072 paste Substances 0.000 claims abstract description 13
230000002496 gastric effect Effects 0.000 claims abstract description 12
210000002200 mouth mucosa Anatomy 0.000 claims abstract description 12
230000032683 aging Effects 0.000 claims abstract description 10
230000007794 irritation Effects 0.000 claims abstract description 9
239000006071 cream Substances 0.000 claims abstract description 8
208000035475 disorder Diseases 0.000 claims abstract description 7
239000006210 lotion Substances 0.000 claims abstract description 7
208000002847 Surgical Wound Diseases 0.000 claims abstract description 6
239000000839 emulsion Substances 0.000 claims abstract description 6
239000011505 plaster Substances 0.000 claims abstract description 6
239000007921 spray Substances 0.000 claims abstract description 6
150000001720 carbohydrates Chemical class 0.000 claims description 71
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims description 67
229960004291 sucralfate Drugs 0.000 claims description 67
229930006000 Sucrose Natural products 0.000 claims description 44
239000005720 sucrose Substances 0.000 claims description 44
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 43
239000000203 mixture Substances 0.000 claims description 32
239000000126 substance Substances 0.000 claims description 25
210000004877 mucosa Anatomy 0.000 claims description 23
239000000825 pharmaceutical preparation Substances 0.000 claims description 13
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 12
208000010668 atopic eczema Diseases 0.000 claims description 11
229920002674 hyaluronan Polymers 0.000 claims description 11
229960003160 hyaluronic acid Drugs 0.000 claims description 11
229940090044 injection Drugs 0.000 claims description 11
238000002347 injection Methods 0.000 claims description 11
239000007924 injection Substances 0.000 claims description 11
230000009885 systemic effect Effects 0.000 claims description 11
230000029663 wound healing Effects 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 9
229910052700 potassium Inorganic materials 0.000 claims description 9
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 7
230000000172 allergic effect Effects 0.000 claims description 7
229910052782 aluminium Inorganic materials 0.000 claims description 7
230000002458 infectious effect Effects 0.000 claims description 6
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
239000004411 aluminium Substances 0.000 claims description 5
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 5
150000001413 amino acids Chemical class 0.000 claims description 5
229910052788 barium Inorganic materials 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
229940012356 eye drops Drugs 0.000 claims description 5
150000004676 glycans Chemical class 0.000 claims description 5
238000002513 implantation Methods 0.000 claims description 5
229910052749 magnesium Inorganic materials 0.000 claims description 5
229910052751 metal Inorganic materials 0.000 claims description 5
239000002184 metal Substances 0.000 claims description 5
150000007530 organic bases Chemical group 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
229920001282 polysaccharide Polymers 0.000 claims description 5
239000005017 polysaccharide Substances 0.000 claims description 5
239000011591 potassium Substances 0.000 claims description 5
239000011734 sodium Substances 0.000 claims description 5
229910052708 sodium Inorganic materials 0.000 claims description 5
229910052726 zirconium Inorganic materials 0.000 claims description 5
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 4
229930091371 Fructose Natural products 0.000 claims description 4
239000005715 Fructose Substances 0.000 claims description 4
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
150000001342 alkaline earth metals Chemical class 0.000 claims description 4
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
229910052791 calcium Inorganic materials 0.000 claims description 4
229910052802 copper Inorganic materials 0.000 claims description 4
239000003889 eye drop Substances 0.000 claims description 4
239000008103 glucose Substances 0.000 claims description 4
239000008101 lactose Substances 0.000 claims description 4
229910052748 manganese Inorganic materials 0.000 claims description 4
229910052762 osmium Inorganic materials 0.000 claims description 4
159000000000 sodium salts Chemical class 0.000 claims description 4
229910052725 zinc Inorganic materials 0.000 claims description 4
239000003513 alkali Substances 0.000 claims description 3
239000007923 nasal drop Substances 0.000 claims description 3
239000006216 vaginal suppository Substances 0.000 claims description 3
229940120293 vaginal suppository Drugs 0.000 claims description 3
208000026935 allergic disease Diseases 0.000 claims description 2
230000007815 allergy Effects 0.000 claims description 2
229910021653 sulphate ion Inorganic materials 0.000 claims description 2
WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical group OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims 3
230000002262 irrigation Effects 0.000 claims 2
238000003973 irrigation Methods 0.000 claims 2
229940100652 nasal gel Drugs 0.000 claims 2
229940100657 nasal ointment Drugs 0.000 claims 2
239000007922 nasal spray Substances 0.000 claims 2
229940044959 vaginal cream Drugs 0.000 claims 2
239000000522 vaginal cream Substances 0.000 claims 2
229940044950 vaginal gel Drugs 0.000 claims 2
239000000029 vaginal gel Substances 0.000 claims 2
229940044977 vaginal tablet Drugs 0.000 claims 2
239000000003 vaginal tablet Substances 0.000 claims 2
229910052783 alkali metal Inorganic materials 0.000 claims 1
150000001340 alkali metals Chemical class 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
210000002345 respiratory system Anatomy 0.000 claims 1
210000001215 vagina Anatomy 0.000 claims 1
210000003905 vulva Anatomy 0.000 claims 1
208000025865 Ulcer Diseases 0.000 abstract description 18
230000036269 ulceration Effects 0.000 abstract description 11
230000003902 lesion Effects 0.000 abstract description 4
230000004048 modification Effects 0.000 abstract description 2
238000012986 modification Methods 0.000 abstract description 2
230000008439 repair process Effects 0.000 abstract description 2
208000034693 Laceration Diseases 0.000 abstract 1
230000008105 immune reaction Effects 0.000 abstract 1
210000003491 skin Anatomy 0.000 description 49
210000001508 eye Anatomy 0.000 description 27
230000000694 effects Effects 0.000 description 26
230000003110 anti-inflammatory effect Effects 0.000 description 24
206010052428 Wound Diseases 0.000 description 23
208000027418 Wounds and injury Diseases 0.000 description 23
238000012360 testing method Methods 0.000 description 22
210000004027 cell Anatomy 0.000 description 14
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
239000004615 ingredient Substances 0.000 description 14
241000282472 Canis lupus familiaris Species 0.000 description 13
241000282326 Felis catus Species 0.000 description 13
238000002560 therapeutic procedure Methods 0.000 description 13
206010015150 Erythema Diseases 0.000 description 12
229940079593 drug Drugs 0.000 description 12
239000002245 particle Substances 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
231100000321 erythema Toxicity 0.000 description 11
208000002193 Pain Diseases 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
201000004624 Dermatitis Diseases 0.000 description 9
201000004681 Psoriasis Diseases 0.000 description 9
230000006872 improvement Effects 0.000 description 9
238000001356 surgical procedure Methods 0.000 description 9
230000001684 chronic effect Effects 0.000 description 8
239000003240 coconut oil Substances 0.000 description 8
235000019864 coconut oil Nutrition 0.000 description 8
230000002757 inflammatory effect Effects 0.000 description 8
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 8
108010010803 Gelatin Proteins 0.000 description 7
206010030113 Oedema Diseases 0.000 description 7
230000001154 acute effect Effects 0.000 description 7
230000037396 body weight Effects 0.000 description 7
235000010948 carboxy methyl cellulose Nutrition 0.000 description 7
201000010099 disease Diseases 0.000 description 7
239000008273 gelatin Substances 0.000 description 7
229920000159 gelatin Polymers 0.000 description 7
229940014259 gelatin Drugs 0.000 description 7
235000019322 gelatine Nutrition 0.000 description 7
235000011852 gelatine desserts Nutrition 0.000 description 7
229960000905 indomethacin Drugs 0.000 description 7
238000000034 method Methods 0.000 description 7
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
235000010987 pectin Nutrition 0.000 description 7
239000001814 pectin Substances 0.000 description 7
229960000292 pectin Drugs 0.000 description 7
206010037844 rash Diseases 0.000 description 7
150000003431 steroids Chemical class 0.000 description 7
229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
102000001974 Hyaluronidases Human genes 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
230000002924 anti-infective effect Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
210000000795 conjunctiva Anatomy 0.000 description 6
238000007455 ileostomy Methods 0.000 description 6
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
229920001277 pectin Polymers 0.000 description 6
230000009467 reduction Effects 0.000 description 6
231100000397 ulcer Toxicity 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
241000700198 Cavia Species 0.000 description 5
206010012438 Dermatitis atopic Diseases 0.000 description 5
208000003251 Pruritus Diseases 0.000 description 5
208000007536 Thrombosis Diseases 0.000 description 5
201000008937 atopic dermatitis Diseases 0.000 description 5
239000001768 carboxy methyl cellulose Substances 0.000 description 5
239000008112 carboxymethyl-cellulose Substances 0.000 description 5
229940105329 carboxymethylcellulose Drugs 0.000 description 5
239000000306 component Substances 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000003862 glucocorticoid Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
210000003205 muscle Anatomy 0.000 description 5
-1 or A1 Substances 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
208000017520 skin disease Diseases 0.000 description 5
229940037128 systemic glucocorticoids Drugs 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
208000010201 Exanthema Diseases 0.000 description 4
229920002683 Glycosaminoglycan Polymers 0.000 description 4
108050009363 Hyaluronidases Proteins 0.000 description 4
102000000588 Interleukin-2 Human genes 0.000 description 4
108010002350 Interleukin-2 Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
206010042496 Sunburn Diseases 0.000 description 4
206010000496 acne Diseases 0.000 description 4
229940124599 anti-inflammatory drug Drugs 0.000 description 4
239000007900 aqueous suspension Substances 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
210000004087 cornea Anatomy 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
201000005884 exanthem Diseases 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
239000007970 homogeneous dispersion Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
230000000051 modifying effect Effects 0.000 description 4
229920001296 polysiloxane Polymers 0.000 description 4
150000003180 prostaglandins Chemical class 0.000 description 4
230000028327 secretion Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
229940100615 topical ointment Drugs 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
208000002874 Acne Vulgaris Diseases 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 3
208000035473 Communicable disease Diseases 0.000 description 3
206010010741 Conjunctivitis Diseases 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
206010016936 Folliculitis Diseases 0.000 description 3
206010017533 Fungal infection Diseases 0.000 description 3
102000008070 Interferon-gamma Human genes 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
208000031888 Mycoses Diseases 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
208000008469 Peptic Ulcer Diseases 0.000 description 3
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010039101 Rhinorrhoea Diseases 0.000 description 3
206010072170 Skin wound Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000033809 Suppuration Diseases 0.000 description 3
241000700605 Viruses Species 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
239000002260 anti-inflammatory agent Substances 0.000 description 3
229940121363 anti-inflammatory agent Drugs 0.000 description 3
230000000845 anti-microbial effect Effects 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
239000002537 cosmetic Substances 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
239000006196 drop Substances 0.000 description 3
208000026278 immune system disease Diseases 0.000 description 3
206010022000 influenza Diseases 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000000554 iris Anatomy 0.000 description 3
239000002085 irritant Substances 0.000 description 3
231100000021 irritant Toxicity 0.000 description 3
230000002045 lasting effect Effects 0.000 description 3
230000002132 lysosomal effect Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
206010039083 rhinitis Diseases 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
238000005728 strengthening Methods 0.000 description 3
230000003319 supportive effect Effects 0.000 description 3
201000000596 systemic lupus erythematosus Diseases 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010004146 Basal cell carcinoma Diseases 0.000 description 2
208000019838 Blood disease Diseases 0.000 description 2
241000222120 Candida <Saccharomycetales> Species 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
206010010539 Congenital megacolon Diseases 0.000 description 2
206010048768 Dermatosis Diseases 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
206010051814 Eschar Diseases 0.000 description 2
206010063560 Excessive granulation tissue Diseases 0.000 description 2
208000001640 Fibromyalgia Diseases 0.000 description 2
229920002971 Heparan sulfate Polymers 0.000 description 2
208000004592 Hirschsprung disease Diseases 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
108010003272 Hyaluronate lyase Proteins 0.000 description 2
201000009053 Neurodermatitis Diseases 0.000 description 2
206010035669 Pneumonia aspiration Diseases 0.000 description 2
206010037888 Rash pustular Diseases 0.000 description 2
230000010757 Reduction Activity Effects 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
206010039705 Scleritis Diseases 0.000 description 2
206010039710 Scleroderma Diseases 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
206010040943 Skin Ulcer Diseases 0.000 description 2
206010040880 Skin irritation Diseases 0.000 description 2
208000007107 Stomach Ulcer Diseases 0.000 description 2
206010042566 Superinfection Diseases 0.000 description 2
208000002474 Tinea Diseases 0.000 description 2
241000893966 Trichophyton verrucosum Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000003266 anti-allergic effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
201000009807 aspiration pneumonia Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
231100001015 blood dyscrasias Toxicity 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000003518 caustics Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
230000008859 change Effects 0.000 description 2
229960003677 chloroquine Drugs 0.000 description 2
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
201000009151 chronic rhinitis Diseases 0.000 description 2
230000007012 clinical effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000006378 damage Effects 0.000 description 2
231100000333 eschar Toxicity 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
210000000744 eyelid Anatomy 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
210000001126 granulation tissue Anatomy 0.000 description 2
230000035876 healing Effects 0.000 description 2
208000014951 hematologic disease Diseases 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
208000018706 hematopoietic system disease Diseases 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
229960002773 hyaluronidase Drugs 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
238000010874 in vitro model Methods 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
206010023332 keratitis Diseases 0.000 description 2
150000002617 leukotrienes Chemical class 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
201000004792 malaria Diseases 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
208000010753 nasal discharge Diseases 0.000 description 2
229940100662 nasal drops Drugs 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
150000002482 oligosaccharides Polymers 0.000 description 2
206010033675 panniculitis Diseases 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229960002895 phenylbutazone Drugs 0.000 description 2
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
208000029561 pustule Diseases 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
230000004044 response Effects 0.000 description 2
201000004700 rosacea Diseases 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
231100000475 skin irritation Toxicity 0.000 description 2
230000036556 skin irritation Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
210000004304 subcutaneous tissue Anatomy 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
201000002282 venous insufficiency Diseases 0.000 description 2
230000037303 wrinkles Effects 0.000 description 2
OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
DILISPNYIVRDBP-UHFFFAOYSA-N 2-[3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]-2-naphthalen-2-ylimidazol-4-yl]acetonitrile Chemical compound OC(CNC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=CC2=CC=CC=C2C=C1)C DILISPNYIVRDBP-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
206010001076 Acute sinusitis Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
201000010000 Agranulocytosis Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
241000086254 Arnica montana Species 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
206010007027 Calculus urinary Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
206010007247 Carbuncle Diseases 0.000 description 1
235000013913 Ceratonia Nutrition 0.000 description 1
241001060815 Ceratonia Species 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
241001608562 Chalazion Species 0.000 description 1
235000007866 Chamaemelum nobile Nutrition 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920002567 Chondroitin Polymers 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
206010009137 Chronic sinusitis Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
206010010726 Conjunctival oedema Diseases 0.000 description 1
208000034657 Convalescence Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
208000001840 Dandruff Diseases 0.000 description 1
206010011985 Decubitus ulcer Diseases 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012444 Dermatitis diaper Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000003105 Diaper Rash Diseases 0.000 description 1
208000019872 Drug Eruptions Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
201000011275 Epicondylitis Diseases 0.000 description 1
206010015084 Episcleritis Diseases 0.000 description 1
206010015218 Erythema multiforme Diseases 0.000 description 1
206010015226 Erythema nodosum Diseases 0.000 description 1
206010016228 Fasciitis Diseases 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
241000227647 Fucus vesiculosus Species 0.000 description 1
206010017543 Fungal skin infection Diseases 0.000 description 1
206010017553 Furuncle Diseases 0.000 description 1
IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229920000569 Gum karaya Polymers 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
208000004898 Herpes Labialis Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000004575 Infectious Arthritis Diseases 0.000 description 1
206010022941 Iridocyclitis Diseases 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
206010023204 Joint dislocation Diseases 0.000 description 1
206010023230 Joint stiffness Diseases 0.000 description 1
206010023232 Joint swelling Diseases 0.000 description 1
229940124091 Keratolytic Drugs 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
108010093008 Kinins Proteins 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010023927 Lassa fever Diseases 0.000 description 1
208000005230 Leg Ulcer Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
244000042664 Matricaria chamomilla Species 0.000 description 1
235000007232 Matricaria chamomilla Nutrition 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
244000062730 Melissa officinalis Species 0.000 description 1
235000010654 Melissa officinalis Nutrition 0.000 description 1
241001448624 Miliaria Species 0.000 description 1
208000037039 Monarthritis Diseases 0.000 description 1
206010067994 Mucosal atrophy Diseases 0.000 description 1
208000023178 Musculoskeletal disease Diseases 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
206010061302 Myringitis Diseases 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
206010028748 Nasal obstruction Diseases 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
206010054107 Nodule Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
206010067152 Oral herpes Diseases 0.000 description 1
206010031149 Osteitis Diseases 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
206010033079 Otitis media acute Diseases 0.000 description 1
208000025690 Otorhinolaryngologic disease Diseases 0.000 description 1
206010033102 Otosalpingitis Diseases 0.000 description 1
206010033733 Papule Diseases 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
241000101040 Pityriasis Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
208000036741 Pruritus generalised Diseases 0.000 description 1
206010037508 Punctate keratitis Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
208000036071 Rhinorrhea Diseases 0.000 description 1
241001303601 Rosacea Species 0.000 description 1
206010039792 Seborrhoea Diseases 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
206010040799 Skin atrophy Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
201000002661 Spondylitis Diseases 0.000 description 1
208000010040 Sprains and Strains Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010041955 Stasis dermatitis Diseases 0.000 description 1
208000005279 Status Asthmaticus Diseases 0.000 description 1
241000934878 Sterculia Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043248 Tendon rupture Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
208000004760 Tenosynovitis Diseases 0.000 description 1
206010053615 Thermal burn Diseases 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
206010046914 Vaginal infection Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000726445 Viroids Species 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000003152 Yellow Fever Diseases 0.000 description 1
QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000011629 acute eustachian salpingitis Diseases 0.000 description 1
201000001930 acute serous otitis media Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
239000013566 allergen Substances 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000003868 ammonium compounds Chemical class 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
201000004612 anterior uveitis Diseases 0.000 description 1
230000003255 anti-acne Effects 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
201000009087 atopic dermatitis 6 Diseases 0.000 description 1
201000009221 atopic dermatitis 8 Diseases 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
AEMOLEFTQBMNLQ-DTEWXJGMSA-N beta-D-galacturonic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
208000006766 bile reflux Diseases 0.000 description 1
208000010217 blepharitis Diseases 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
210000003103 bodily secretion Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
208000018339 bone inflammation disease Diseases 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
210000005252 bulbus oculi Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940043431 ceratonia Drugs 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
208000002849 chondrocalcinosis Diseases 0.000 description 1
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
208000027157 chronic rhinosinusitis Diseases 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
238000012321 colectomy Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000004154 complement system Effects 0.000 description 1
208000027744 congestion Diseases 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
238000001804 debridement Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
102000038379 digestive enzymes Human genes 0.000 description 1
108091007734 digestive enzymes Proteins 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
229960001275 dimeticone Drugs 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000003618 dip coating Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
210000000959 ear middle Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
208000004000 erythrasma Diseases 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
229940044949 eucalyptus oil Drugs 0.000 description 1
239000010642 eucalyptus oil Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
208000024711 extrinsic asthma Diseases 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
230000006870 function Effects 0.000 description 1
208000003512 furunculosis Diseases 0.000 description 1
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229960001731 gluceptate Drugs 0.000 description 1
KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000002343 gold Chemical class 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
238000011554 guinea pig model Methods 0.000 description 1
235000019314 gum ghatti Nutrition 0.000 description 1
210000004209 hair Anatomy 0.000 description 1
KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
229910000271 hectorite Inorganic materials 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
208000014617 hemorrhoid Diseases 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
239000012676 herbal extract Substances 0.000 description 1
208000002557 hidradenitis Diseases 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
208000008025 hordeolum Diseases 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
238000009802 hysterectomy Methods 0.000 description 1
206010021198 ichthyosis Diseases 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
201000001371 inclusion conjunctivitis Diseases 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
238000002664 inhalation therapy Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000009434 installation Methods 0.000 description 1
208000005005 intertrigo Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
201000010659 intrinsic asthma Diseases 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229940063644 ispaghula husk Drugs 0.000 description 1
230000007803 itching Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
235000010494 karaya gum Nutrition 0.000 description 1
239000000231 karaya gum Substances 0.000 description 1
229940039371 karaya gum Drugs 0.000 description 1
230000001530 keratinolytic effect Effects 0.000 description 1
239000003410 keratolytic agent Substances 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
208000025036 lymphosarcoma Diseases 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
238000002803 maceration Methods 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000005741 malignant process Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
229940100656 nasal solution Drugs 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000010606 normalization Methods 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
230000000771 oncological effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
150000002907 osmium Chemical class 0.000 description 1
206010033072 otitis externa Diseases 0.000 description 1
201000009838 otomycosis Diseases 0.000 description 1
UWBHMRBRLOJJAA-UHFFFAOYSA-N oxaluric acid Chemical compound NC(=O)NC(=O)C(O)=O UWBHMRBRLOJJAA-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000011088 parchment paper Substances 0.000 description 1
235000021401 pellet diet Nutrition 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
206010035653 pneumoconiosis Diseases 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
125000003259 prostaglandin group Chemical group 0.000 description 1
230000001823 pruritic effect Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
230000005855 radiation Effects 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
210000001732 sebaceous gland Anatomy 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000035807 sensation Effects 0.000 description 1
201000001223 septic arthritis Diseases 0.000 description 1
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
206010040400 serum sickness Diseases 0.000 description 1
238000004904 shortening Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
206010041232 sneezing Diseases 0.000 description 1
239000000344 soap Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940101569 sucralfate 100 mg/ml Drugs 0.000 description 1
125000000185 sucrose group Chemical group 0.000 description 1
MBTJHFXKYOUFMC-UJPDDDSFSA-N sulfuric acid;(2r,3s,4r)-2,3,4,5-tetrahydroxypentanal Chemical compound OS(O)(=O)=O.OC[C@@H](O)[C@H](O)[C@@H](O)C=O MBTJHFXKYOUFMC-UJPDDDSFSA-N 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
210000000106 sweat gland Anatomy 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
229940098956 topical powder Drugs 0.000 description 1
206010044325 trachoma Diseases 0.000 description 1
230000008733 trauma Effects 0.000 description 1
201000002311 trypanosomiasis Diseases 0.000 description 1
208000025301 tympanitis Diseases 0.000 description 1
230000001562 ulcerogenic effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
208000008281 urolithiasis Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000003934 vacuole Anatomy 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
208000002003 vulvitis Diseases 0.000 description 1
208000010484 vulvovaginitis Diseases 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1